Gritstone bio, Inc.

GRTS

US39868T1051

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:49:33 2024-04-26 am EDT			5-day change	1st Jan Change
0.776 ^USD	+1.50%		+3.80%	-62.52%

Apr. 15	Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	CI
Apr. 02	Top Midday Decliners	MT

Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier Management, L.L.C., Gilead Sciences, Inc., Redmile Group, LLC, Lighthouse Investment Partners, LLC and other investors

September 16, 2021

On September 17, 2021, Gritstone bio, Inc. closed the transaction. The company received funding from 10 investors pursuant to exemption provided under Regulation D.

Latest news about Gritstone bio, Inc.

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	Apr. 15	CI
Top Midday Decliners	Apr. 02	MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	Apr. 02	MT
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	Apr. 01	MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	Apr. 01	MT
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	Apr. 01	CI
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M	Mar. 05	MT
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial	Feb. 12	CI
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating	Dec. 07	MT
Transcript : Gritstone bio, Inc. Presents at First Annual Goldman Sachs Catalyst Clinic, Dec-05-2023 11:00 AM	Dec. 05
Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $1.6M	Nov. 08	MT
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023	23-10-11	CI
Gritstone bio Offers Stock Options to Three New Employees	23-10-10	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28	MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating	23-09-28	MT
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours	23-09-27	MT
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19	23-09-27	CI
Gritstone bio, Genevant Sciences Sign License Agreement for Use of LNP Technology	23-08-15	MT
Gritstone Bio and Genevant Sciences Announce Option and License Agreement	23-08-15	CI
Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $2M	23-08-09	MT
Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Gritstone Joins Collaborative Cancer Research Initiative; Shares Rise 4% Pre-Bell	23-08-07	MT

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Neoantigen International Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Gritstone bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7645 USD

Average target price

5.167 USD

Spread / Average Target

+575.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRITSTONE BIO, INC.	-62.52%	81.34M
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-22.49%	29.48B
UCB	+56.72%	25.43B
INCYTE CORPORATION	-18.03%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+4.64%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals